Special Issues

IO- Immuno-Oncology - Summer 2026 Issue
Volume: 1
Issue: 1

Contemporary Oncology®: Biomarkers, Pathways, and Targeted Therapies® - January 2024
Volume: 1
Issue: 1

Oncology Live Urologists in Cancer Care®: July 2023
Volume: 1
Issue: 1

November 2022

Oncology Live Urologists in Cancer Care®: July 2022
Volume: 1
Issue: 1

IO - Immuno-Oncology - July 2022 Issue
Volume: 1
Issue: 1

Contemporary Oncology®: Biomarkers, Pathways, and Targeted Therapies® - May 2022
Volume: 1
Issue: 1

Oncology Business News®: April 2022
Volume: 1
Issue: 1

March 2022

March 2021

SABCS 2019: Updates in HER2+ Breast Cancer
Volume: 1
Issue: 1

Emerging MOAs in Multiple Myeloma: Updates From the 17th IMW
Volume: 1
Issue: 1

August 2019
Volume: 8
Issue: 4

Developments in NRG1 Fusion+ Cancers
Volume: 1
Issue: 1

June 2019
Volume: 8
Issue: 3

Therapeutic Advances in Hairy Cell Leukemia
Volume: 1
Issue: 1

The Changing Chronic Lymphocytic Leukemia Treatment Paradigm
Volume: 1
Issue: 1

Management of Diarrhea in Breast Cancer
Volume: 1
Issue: 1

Updates in Next-Generation Sequencing
Volume: 1
Issue: 1

April 2019
Volume: 8
Issue: 2

The Role of Folate Receptor Alpha in the Treatment of Ovarian Cancer
Volume: 1
Issue: 1

Therapeutic Developments in Acute Myeloid Leukemia
Volume: 1
Issue: 1

February 2019
Volume: 8
Issue: 1

Focus on Pathways: Inhibition of the BCL-2 Pathway in Hematologic Malignancies
Volume: 1
Issue: 1

ASCO 2019: Therapeutic Updates in Melanoma
Volume: 1
Issue: 1

Focus on Pathways: Historical Perspective and Current Considerations in Hairy Cell Leukemia

December 2018
Volume: 7
Issue: 6

FGFR Inhibition in Cholangiocarcinoma: Update from the 2018 ESMO Congress
Volume: 1
Issue: 1

October 2018
Volume: 7
Issue: 5

The Rationale for Bruton Tyrosine Kinase Inhibition in B-Cell Lymphomas
Advertisement
Advertisement
Trending on OncLive
1
Stay Ahead of ESMO 2026: See What Lung Cancer Experts Are Prioritizing
2
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
3
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
4
Talquetamab Plus Daratumumab Earns CHMP Backing in R/R Myeloma
5
